Nektar Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: NKTR · Form: 8-K · Filed: May 28, 2025 · CIK: 906709
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: NKTR
TL;DR
Nektar Therapeutics (NKTR) filed an 8-K for a shareholder vote on May 23rd.
AI Summary
Nektar Therapeutics filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of security holders as of May 23, 2025. The filing details the company's principal executive offices located at 455 Mission Bay Boulevard South, San Francisco, California.
Why It Matters
This filing indicates that Nektar Therapeutics held a vote of its security holders, which is a standard corporate governance event that can signal important decisions or approvals by the company's shareholders.
Risk Assessment
Risk Level: low — This is a routine corporate filing regarding a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- May 27, 2025 (date) — Date of earliest event reported
- May 23, 2025 (date) — Date of report
- 455 Mission Bay Boulevard South, San Francisco, California 94158 (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Nektar Therapeutics' security holders?
The filing does not specify the exact matters voted upon, only that matters were submitted for a vote as of May 23, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 23, 2025.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is the SEC file number for Nektar Therapeutics?
The SEC file number for Nektar Therapeutics is 000-24006.
What is the IRS Employer Identification Number for Nektar Therapeutics?
The IRS Employer Identification Number for Nektar Therapeutics is 94-3134940.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding NEKTAR THERAPEUTICS (NKTR).